Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology

W. H. Van Harten*, V. P. Retèl

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)
35 Downloads (Pure)

Abstract

The Organisation of European Cancer Institutes OECI working group on Health Economics and Cost Benefit in Oncology suggests four actions that are needed to improve alignment and integration between clinicians, researchers, and Health Technology Assessment (HTA) experts and agencies: 1) HTA expertise is necessary close to or within the comprehensive cancer centres (CCC); 2) HTA expertise should be physically present throughout the translational research process; 3) Appropriate knowledge is necessary within the research staff; 4) Close cooperation between translational researchers, clinicians, and health economists guarantees clinical ownership. Fulfilling these conditions may help the translational research field in oncology to interact with agencies and efficiently move innovative technologies through the translational research stages into that of implementation and diffusion. This brings innovative treatments faster to the patient with a greater chance of reimbursement.

Original languageEnglish
Article number686
JournalEcancermedicalscience
Volume10
DOIs
Publication statusPublished - 28 Oct 2016

Fingerprint

Biomedical Technology Assessment
Translational Medical Research
Research Personnel
Ownership
Insurance Benefits
Health Care Costs
Cost-Benefit Analysis
Neoplasms
Economics
Organizations
Technology
Health
Research
Therapeutics

Keywords

  • Collaboration
  • Health technology assessment
  • Innovations
  • Oncology practice

Cite this

@article{fb131372b3114061b51d690e9d608f01,
title = "Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology",
abstract = "The Organisation of European Cancer Institutes OECI working group on Health Economics and Cost Benefit in Oncology suggests four actions that are needed to improve alignment and integration between clinicians, researchers, and Health Technology Assessment (HTA) experts and agencies: 1) HTA expertise is necessary close to or within the comprehensive cancer centres (CCC); 2) HTA expertise should be physically present throughout the translational research process; 3) Appropriate knowledge is necessary within the research staff; 4) Close cooperation between translational researchers, clinicians, and health economists guarantees clinical ownership. Fulfilling these conditions may help the translational research field in oncology to interact with agencies and efficiently move innovative technologies through the translational research stages into that of implementation and diffusion. This brings innovative treatments faster to the patient with a greater chance of reimbursement.",
keywords = "Collaboration, Health technology assessment, Innovations, Oncology practice",
author = "{Van Harten}, {W. H.} and Ret{\`e}l, {V. P.}",
year = "2016",
month = "10",
day = "28",
doi = "10.3332/ecancer.2016.686",
language = "English",
volume = "10",
journal = "Ecancermedicalscience",
issn = "1754-6605",
publisher = "Cancer Intellilgence",

}

TY - JOUR

T1 - Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology

AU - Van Harten, W. H.

AU - Retèl, V. P.

PY - 2016/10/28

Y1 - 2016/10/28

N2 - The Organisation of European Cancer Institutes OECI working group on Health Economics and Cost Benefit in Oncology suggests four actions that are needed to improve alignment and integration between clinicians, researchers, and Health Technology Assessment (HTA) experts and agencies: 1) HTA expertise is necessary close to or within the comprehensive cancer centres (CCC); 2) HTA expertise should be physically present throughout the translational research process; 3) Appropriate knowledge is necessary within the research staff; 4) Close cooperation between translational researchers, clinicians, and health economists guarantees clinical ownership. Fulfilling these conditions may help the translational research field in oncology to interact with agencies and efficiently move innovative technologies through the translational research stages into that of implementation and diffusion. This brings innovative treatments faster to the patient with a greater chance of reimbursement.

AB - The Organisation of European Cancer Institutes OECI working group on Health Economics and Cost Benefit in Oncology suggests four actions that are needed to improve alignment and integration between clinicians, researchers, and Health Technology Assessment (HTA) experts and agencies: 1) HTA expertise is necessary close to or within the comprehensive cancer centres (CCC); 2) HTA expertise should be physically present throughout the translational research process; 3) Appropriate knowledge is necessary within the research staff; 4) Close cooperation between translational researchers, clinicians, and health economists guarantees clinical ownership. Fulfilling these conditions may help the translational research field in oncology to interact with agencies and efficiently move innovative technologies through the translational research stages into that of implementation and diffusion. This brings innovative treatments faster to the patient with a greater chance of reimbursement.

KW - Collaboration

KW - Health technology assessment

KW - Innovations

KW - Oncology practice

UR - http://www.scopus.com/inward/record.url?scp=84996561769&partnerID=8YFLogxK

U2 - 10.3332/ecancer.2016.686

DO - 10.3332/ecancer.2016.686

M3 - Article

AN - SCOPUS:84996561769

VL - 10

JO - Ecancermedicalscience

JF - Ecancermedicalscience

SN - 1754-6605

M1 - 686

ER -